recombinant C1 esterase inhibitor; recombinant C1 INH
Jump to navigation
Jump to search
Indications
- hereditary angioedema
- treatment of acute attacks & prevention ?
Dosage
- SQ twice weekly
Pharmacokinetics
- much shorter 1/2life) than human plasma-derived C1 esterase inhibitor[1]
Notes
- benefit of a recombinant product is a theoretically limitless supply without worry about bloodborne pathogens[1]
More general terms
References
- ↑ 1.0 1.1 1.2 Riedl MA, Grivcheva-Panovska V, Moldovan D et al. Recombinant human C1 esterase inhibitor for prophylaxis of hereditary angio-oedema: A phase 2, multicentre, randomised, double-blind, placebo-controlled crossover trial. Lancet 2017 Jul 25; PMID: https://www.ncbi.nlm.nih.gov/pubmed/28754491
Greve J, Hahn J. Recombinant human C1 esterase inhibitor for hereditary angio- oedema. Lancet 2017 Jul 25; PMID: https://www.ncbi.nlm.nih.gov/pubmed/28754495